Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268150 | 0.98 | HPGD (0.50) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6273913 | 0.93 | RAB9A (0.49) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6272365 | 0.91 | RAB9A (0.46) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6137896 | 0.82 | RAB9A (0.56) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6272359 | 0.81 | TDP1 (0.38) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL8244324 | 0.81 | HPGD (0.53) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL11356392 | 0.81 | HPGD (0.53) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL13546279 | 0.80 | RAB9A (0.53) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6273628 | 0.80 | EPHX1 (0.35) | HPGDKMT2AEPHX1RAB9ANPC1 | |
| SCHEMBL6273398 | 0.79 | KCNH2 (0.35) | HPGDKMT2AEPHX1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | claimed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | HPGD 534/4885KMT2A 3330/4885EPHX1 958/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | HPGD 534/4885KMT2A 3330/4885EPHX1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.